News on diagnostics for respiratory pathogens, including influenza, coronavirus, and more.
ProAxsis and a US-based biotechnology company codeveloped the assay as part of an ongoing collaboration. ProAxsis has made its first commercial sale of the test.
In a study of 264 men suspected of having sleep apnea, the three-marker panel outperformed several existing clinical measures for diagnosing the condition.
